Study Group: Twinject Prescribers (US)(?)
Council Members in this Study Group: 19
Request a survey with this Study Group
Leading Experts in this Study Group
Michael Blaiss, MD
Partner
Allergy & Asthma Care
Michael S. Blaiss, MD, is a Clinical Professor of Pediatrics and Medicine at University of Tennessee Health Sciences Center and in private practice at Allergy & Asthma Care in Memphis. Dr. Blaiss’s clinical focus is on allergies and has expertise in outcomes research in allergic disorders, especially...
Director
Allergy and Asthma Specialists Medical Group & Research Center
Steven Weinstein, MD, is the Director of Allergy and Asthma Specialists Medical Group and Research Center, California. He also holds an academic appointment as Clinical Professor of Allergy and Immunology in the Department of Pediatrics at the University of California, Irvine, School of Medicine. Dr....
Allergy Specialist and Partner
Allergy & Asthma Consultants Of The Ozarks Ltd
Mark Vandewalker, MD, is an Allergy Specialist at Allergy and Asthma Consultants and he is the Medical Director at Clinical Research of the Ozarks in Missouri. Dr. Vandewalker is board-certified in Pediatric Allergy and has been practicing for almost 25 years. His areas of expertise include allergic...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Epipen Prescribers (US) | 37 |
| Pediatric Allergist Physicians in the U.S. | 133 |
| Pediatric Allergy Physicians | 176 |
| Pediatricians (US) | 1678 |
| Allergists (US) | 402 |
| Physicians who Treat Asthma (US) | 458 |
| Pulmonologists (US) | 753 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The use of long-acting beta-agonists (LABAs) in the treatment of persistent asthma has become one of the most controversial issues of respiratory disease management during this decade. Both salmeterol and formoterol have been shown in numerous clinical trials of asthma to dramatically improve pulmonary...
This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant...
Symbicort is AstraZeneca's answer to Advair, presently the number one combination ICS/LABA in the U.S. for treating moderate to severe asthma. Symbicort will not, however, have an indication for quick relief of bronchospasm as it does in many European countries. Nevertheless, Symbicort appears to be...
The black box warning is a real concern to physicians who prescribe Xolair and patients who are taking it. It highlights a risk that has always been there but is apparently more common than previously thought.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Laboratory, Independent
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Partner
- Physician - Director
- Director
- Senior Manager
- President